This injectable combination of piperacillin and tazobactam is a broad-spectrum beta-lactam antibiotic therapy used for the management of moderate to severe bacterial infections caused by susceptible organisms.
Piperacillin acts by inhibiting bacterial cell wall synthesis, while tazobactam protects it from degradation by beta-lactamase enzymes, thereby extending its antibacterial spectrum and improving clinical effectiveness.
It is widely prescribed in respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and hospital-acquired infections, especially in critical care settings.
With rising demand for reliable injectable antibiotics in hospitals and nursing homes, this formulation supports consistent market movement, strengthens institutional reach, and helps businesses expand their portfolio with a high-utility, clinician-trusted critical care product.
Common side effects may include injection site pain, nausea, vomiting, diarrhea, headache, or rash. Rarely, hypersensitivity reactions, electrolyte imbalance, or altered liver and kidney function tests may occur.
Piprazon 2.25 Injection is indicated for the treatment of moderate to severe bacterial infections including respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, gynecological infections, septicemia, and hospital-acquired infections caused by susceptible organisms, as advised by a physician.
For intravenous use only under strict medical supervision. Dosage and duration should be determined by the physician based on infection severity and patient condition. Use with caution in patients with renal impairment or a history of penicillin allergy.
Store below 25°C in a cool, dry place. Protect from light. Reconstituted solution should be used immediately or as directed by a healthcare professional. Keep out of reach of children.